Articles about upcoming approvals and Humira biosimilars were among those that garnered the most interest.
Articles about upcoming approvals and Humira biosimilars were among those that garnered the most interest.
Here are the five articles published in the print publication of Managed Healthcare Executive that had the most pageviews when they were posted on the MHE website.
The approval of Mounjaro (tirzepatide) for weight loss could be a tipping point for weight-loss drugs. [The weight-loss version of tirzepatide is being sold under the brand-name Zepbound.]
As many as 10 Humira biosimilars [it wound up being just 8] may be on the U.S. market before 2023 is over. AbbVie has taken several steps to protect its revenues, including the launches of Skyrizi and Rinvoq.
Pharmacy benefit managers say they exclude high-cost drugs and have alternatives on their formularies. Critics say exclusions narrow patient options and may put effective medication financially out of reach.
Repositories of donated drugs in 13 states are redistributing oncology medications to those in need.
Three ADCs are in late-stage trials as treatments for patients with non-small cell lung cancer.
Conversations With Perry and Friends: Paul Fronstin, Ph.D.
May 9th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. In this episode, his guest is Paul Fronstin, Ph.D., director of health benefits research at the Employee Benefit Research Institute.
Listen
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen